Literature DB >> 3210156

Interindividual changes in volume of distribution of cefazolin in newborn infants and its prediction based on physiological pharmacokinetic concepts.

Y Deguchi1, R Koshida, E Nakashima, R Watanabe, N Taniguchi, F Ichimura, A Tsuji.   

Abstract

The purpose of this study was to investigate factors affecting the volume of distribution of cefazolin (a beta-lactam antibiotic) in newborn infants with bacterial infections, and to propose a method for predicting the volume of distribution at steady state per body weight (Vdss/BW). Cefazolin and tobramycin (an aminoglycoside) were simultaneously given to newborn infants (aged 2 to 28 d), and plasma concentration-time data were analyzed on the basis of model-independent moment analysis. The Vdss/BW values ranged from 0.212 to 0.373 L/kg for cefazolin and from 0.384 to 0.541 L/kg for tobramycin. The unbound fraction of cefazolin in plasma (fp) fluctuated widely, from 0.22 to 0.83, among patients. The Vdss/BW value for cefazolin was characterized by both large extracellular water volume and a remarkable change in fp, and could be predicted as a function of fp using physiological pharmacokinetic concepts. Moreover, interindividual changes in the unconjugated bilirubin:albumin molar ratio were predominantly responsible for the individual variation in the fp values of cefazolin in newborn infants.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3210156     DOI: 10.1002/jps.2600770807

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  11 in total

1.  Population pharmacokinetics of arbekacin, vancomycin, and panipenem in neonates.

Authors:  Toshimi Kimura; Keisuke Sunakawa; Nobuo Matsuura; Hiroaki Kubo; Shigehiko Shimada; Kazuo Yago
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191

Review 2.  Clinical pharmacokinetics of antibacterial drugs in neonates.

Authors:  C M Paap; M C Nahata
Journal:  Clin Pharmacokinet       Date:  1990-10       Impact factor: 6.447

Review 3.  Commonly used antibacterial and antifungal agents for hospitalised paediatric patients: implications for therapy with an emphasis on clinical pharmacokinetics.

Authors:  J Singh; B Burr; D Stringham; A Arrieta
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

4.  An Overview of the Protein Binding of Cephalosporins in Human Body Fluids: A Systematic Review.

Authors:  C Jongmans; A E Muller; P Van Den Broek; B De Melo Cruz De Almeida; C Van Den Berg; J Van Oldenrijk; P K Bos; B C P Koch
Journal:  Front Pharmacol       Date:  2022-06-28       Impact factor: 5.988

5.  Pharmacokinetics and tissue concentrations of cefazolin in pediatric patients undergoing gastrointestinal surgery.

Authors:  M C Nahata; D E Durrell; M E Ginn-Pease; D R King
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1991 Jan-Mar       Impact factor: 2.441

6.  Cefazolin plasma protein binding and its covariates in neonates.

Authors:  A Smits; A Kulo; R Verbesselt; G Naulaers; J de Hoon; P Vermeersch; K Allegaert
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-07-26       Impact factor: 3.267

7.  Pharmacokinetics of prophylactic cefazolin in parturients undergoing cesarean delivery.

Authors:  Mohammed H Elkomy; Pervez Sultan; David R Drover; Ekaterina Epshtein; Jeffery L Galinkin; Brendan Carvalho
Journal:  Antimicrob Agents Chemother       Date:  2014-04-14       Impact factor: 5.191

Review 8.  Pharmacokinetics of cephalosporins in the neonate: a review.

Authors:  Gian Maria Pacifici
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

Review 9.  Impact of Changes in Free Concentrations and Drug-Protein Binding on Drug Dosing Regimens in Special Populations and Disease States.

Authors:  Marie N Celestin; Florin M Musteata
Journal:  J Pharm Sci       Date:  2021-06-02       Impact factor: 3.784

Review 10.  Clinical Pharmacokinetics of Penicillins, Cephalosporins and Aminoglycosides in the Neonate: A Review.

Authors:  Gian Maria Pacifici
Journal:  Pharmaceuticals (Basel)       Date:  2010-08-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.